Johnson & Johnson (JNJ)
Healthcare | Drug Manufacturers - Major
CEO: Alex Gorsky
Johnson & Johnson receives a in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Johnson & Johnson's valuation score is comprised of a P/E ratio of 21.2x, a P/B ratio of 5x, a P/S ratio of 4.9x, and an EV/EBITDA ratio of 14.2x. .
WARREN BUFFETT RANKING
Johnson & Johnson ranks 61 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors.
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Johnson & Johnson appears to have a durable competitive advantage within the Healthcare sector.
Johnson & Johnson has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 26.56x, a debt/equity ratio of 46% and a Moat Rank of 36 translate to a strong Financial Strength score.
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 7.55% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 300.
VALUE + YIELD
Shares currently yield 2.52%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Johnson & Johnson ranks 60 among the S&P 500 constituents.
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. 11.2% 5 year annualized EPS growth, 2% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 4.4% combine to produce this average score.